News

The study, funded by the Medical Research Council and Alzheimer’s Society, involved 295 people who had been diagnosed with moderate to severe Alzheimer’s disease. The main objective of

In the expansion phase of the trial, 448 patients were given an oral formulation of the omecamtiv mecarbil drug for 20 weeks and observed for 24 weeks. Patients

The 33,000 square foot facility provides 25 percent more space than PRA’s previous lab, includes investments in the newest small and large molecule equipment, and allows for optimal

The company said patients taking the FDA-approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking

The company is using its True Human technology for the program. It has started screening human blood samples from donors to detect and clone a therapeutic antibody candidate

Ipsen is developing a new platform of novel neurotoxin derived therapeutics, including TSI, to create new therapeutic opportunities for addressing several medical conditions with unmet requirements. The program

Under the four-year research collaboration, the companies will evaluate the use of CRISPR-Cas9 DNA gene editing technology to address mutations and genes that cause or contribute to cystic

Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In light of the recent allegations made regarding Philidor,

The deal grants Kite an exclusive global license to research, develop and commercialize engineered autologous T cell therapies incorporating two programs from Alpine’s transmembrane immunomodulatory protein (TIP) technology.